Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

mundipharma a/s - morphini sulfas - forðatafla - 10 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - rizatriptanum benzóat - munndreifitafla - 10 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - sumatriptanum súkkínat - tafla - 50 mg

Europeiska unionen - isländska - EMA (European Medicines Agency)

taw pharma (ireland) limited - klópídógrel hýdróklóríð - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - blóðþurrðandi lyf - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Europeiska unionen - isländska - EMA (European Medicines Agency)

orion corporation - algengari ddc hemli, ef - parkinsonsveiki - anti-parkinsonslyf - corbilta er ætlað til meðferðar hjá fullorðnum sjúklingum með parkinsonsveiki og skammtahreyfingar í upphafi skammts sem ekki eru stöðugir á meðferð með levodopa / dopa decarboxylasa (ddc).

Europeiska unionen - isländska - EMA (European Medicines Agency)

orion corporation - algengari ddc hemli, ef - parkinsonsveiki - taugakerfi - algengari/ddc hemli/upplýsingar Úr er ætlað fyrir meðferð fullorðinn sjúklinga með parkinsonsveiki og enda-af-skammt mótor sveiflur ekki á stöðugleika á algengari / dópa-dekarboxýlasa (ddc)-hemil meðferð.

Europeiska unionen - isländska - EMA (European Medicines Agency)

orion corporation - algengari ddc hemli, ef - parkinsonsveiki - anti-parkinsonslyf - stalevo er ætlað til meðferðar hjá fullorðnum sjúklingum með parkinsonsveiki og skammtahreyfingar í upphafi skammts sem ekki eru stöðugir á meðferð með levodopa / dopa-dekarboxylasa (ddc) -hemlandi meðferð.

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

boehringer ingelheim international gmbh* - olodaterolum hýdróklóríð - innöndunarlausn - 2,5 míkróg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

lyfjaver ehf. - levodopum inn; entacaponum inn; carbidopum inn - filmuhúðuð tafla - 150 mg/37,5 mg/200 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - mirtazapinum inn - filmuhúðuð tafla - 30 mg